Geode Capital Management LLC grew its holdings in shares of Alto Neuroscience, Inc. (NYSE:ANRO – Free Report) by 148.7% in ...

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Get Free Report)‘s stock had its “buy” rating reaffirmed by stock analysts at ...

Cereno's expanded access program for investigational therapy CS1 covers 10 PAH patients, following a Phase 2a clinical trial.

Structure Therapeutics has a strong cash position with a runway of 18-20 quarters, but the drug's potential is not fully ...

Topline data from the chronic cohort is expected in Q2 2025Institutional Review Board (IRB) protocol amendment changes ...

Centessa Pharmaceuticals, founded from the merger of 10 biotech companies, is based on an asset-centric model, primarily ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference (RNAi) ...

Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, has enrolled the first 16 of 32 patients in ...

(NASDAQ:MTVA) announced positive topline results from the 16-week Phase 2a clinical trial of DA-1241 in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH). The trial ...